SCHEMBL16239476

SCHEMBL16239476

COc1ccc2c(c1)NC(=O)CC(=O)N2c1ccc(N)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
MAPT P10636 5/20 0.58
RAB9A P51151 1/20 0.58
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
TUBB4A P04350 2/20 0.43
TUBB P07437 2/20 0.43
TUBA3C P0DPH7 2/20 0.43
TUBA1B P68363 2/20 0.43
TUBA4A P68366 2/20 0.43
TUBB4B P68371 2/20 0.43
TUBB3 Q13509 2/20 0.43
TUBB2A Q13885 2/20 0.43
TUBB8 Q3ZCM7 2/20 0.43
TUBA3E Q6PEY2 2/20 0.43
TUBA1A Q71U36 2/20 0.43
TUBA1C Q9BQE3 2/20 0.43
TUBB6 Q9BUF5 2/20 0.43
TUBB2B Q9BVA1 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239073 0.82 MAPT (0.51) MEN1KMT2AMAPTRAB9APDE3B
SCHEMBL28392551 0.79 MAPT (0.47) MEN1KMT2AMAPTRAB9APDE3B
SCHEMBL16239200 0.78 MAPT (0.46) MEN1KMT2AMAPTRAB9APDE3B
SCHEMBL11553211 0.78 PDE3B (0.52) MEN1KMT2AMAPTRAB9APDE3B
SCHEMBL28427593 0.77 MAPT (0.46) MEN1KMT2AMAPTRAB9APDE3B
SCHEMBL16239032 0.74 CREBBP (0.44) MEN1KMT2AMAPTRAB9ASMN1; SMN2
SCHEMBL7701199 0.74 MEN1 (1.00) MEN1KMT2AMAPTRAB9AALDH1A1
SCHEMBL16238949 0.73 P2RX4 (0.64) MEN1KMT2AMAPTRAB9ATUBB4A
SCHEMBL30297416 0.73 P2RX4 (0.64) MEN1KMT2AMAPTRAB9ATUBB4A
SCHEMBL16239146 0.71 MAPT (0.48) MEN1KMT2AMAPTRAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
CN-108863959-B P2X4 receptor antagonists 日本化学药品株式会社 2021-11-30 CN disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
CN-111333588-A P2X4 receptor antagonists 日本化学药品株式会社 2020-06-26 CN disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3285/4885KMT2A 2558/4885MAPT 4732/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3353/4885KMT2A 2156/4885MAPT 4720/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MEN1 3450/4885KMT2A 2174/4885MAPT 4724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.